Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime editing-based pipeline focus to liver disease and programs funded by external ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

The deal would put the DNA data of millions of customers in the hands of a pharmaceutical company, which hopes to supercharge ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

The consumer-genomics company 23andMe just sold its biobank of customer genetic data to drugmaker Regeneron for $256 million.

23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...